Built on a rich legacy of innovation and scientific firsts
BioTime, Inc., parent company of ESI BIO, is a biotechnology company headquartered in the San Francisco Bay Area, focused on biomedical research and product development in regenerative medicine. BioTime and its subsidiary companies focus their research on developing new products and new therapeutics for age-related diseases and acute injuries that affect millions of people in the world today. BioTime’s subsidiary companies ES Cell International (ESI BIO), Cell Cure Neurosciences, LifeMap Sciences, ReCyte Therapeutics. Asterias Biotherapeutics, OncoCyte, and OrthoCyte, focus their research on developing innovative research products and on treating diseases and injuries such as advanced macular degeneration, spinal cord injury, cancer, cartilage repair, and multiple sclerosis. Relatively near-term product development by BioTime and its subsidiaries include Renevia™, a patented hyaluronan-based hydrogel device for cell delivery, and PanC-Dx™, a blood-based pan-cancer screening diagnostic.
BioTime also markets an FDA-approved blood plasma expander called Hextend®, which is currently marketed in the United States in collaboration with Hospira and in South Korea under an agreement with CJ Corporation.